CClinicalTrials.gg
CompletedNCT00962650NOTESUpdated Mar 29, 2012Results posted

Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance

An interventional study of Transgastric diagnostic peritoneoscopy with laparoscopic assistance in Abdominal Adhesions, sponsored by Ethicon Endo-Surgery. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-29.

Sponsored by Ethicon Endo-Surgery · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study will document being able to successfully perform transgastric diagnostic peritoneoscopy (laparoscopic visualization) using a small collection of study surgical tools.

02

Conditions studied

  • Abdominal Adhesions

Browse trials for

Keywords

  • abdominal adhesions
  • diagnostic peritoneoscopy
  • Natural Orifice Transluminal Endoscopic Surgery
  • NOTES
03

In context

Tissue Adhesions

241 studies on the registry are indexed under Tissue Adhesions; 29 are open to participants now.

This study's enrollment of 7 is below the median of 60 across 184 interventional studies indexed under Tissue Adhesions.

Browse Tissue Adhesions studies →

Lead sponsor

Ethicon Endo-Surgery is the lead sponsor of 47 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Men and women will be enrolled in this study who:

  • Are willing to give consent and comply with evaluation and treatment schedule;
  • At least 18 years of age;
  • Are a candidate for surgical weight loss intervention (i.e. meet ASMBS and NIH criteria) for an RYGB procedure at the Investigational site;
  • Have a history of open abdominal surgery or laparoscopic abdominal surgery;
  • ASA Classification I, II, or III (Appendix II); and
  • Have a negative serum pregnancy test (for women of childbearing potential).

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study for any of the following:

  • Use of immunosuppressive medications (within 6 months of surgery; single burst dosages and inhalable steroids are acceptable);
  • Acute cholecystitis or acute pancreatitis;
  • Evidence of abdominal abscess or mass;
  • Diffuse peritonitis;
  • Use of anticoagulants or anti-platelet agents (use of daily cardio protective doses of aspirin, up to 81 mg/day, is acceptable and shall not constitute an exclusion criterion) or the presence of coagulopathy;
  • Clinical diagnosis of sepsis;
  • Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or that could impact the scientific integrity of the trial;
  • Planned concurrent surgical procedure other than RYGB or adhesiolysis;
  • Prior or planned major surgical procedure within 30 days before or after study procedure;
  • Participation in any other investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints;
  • Previously enrolled in the current series of 4 trials investigating the EES NOTES GEN1 Toolbox; or
  • Any condition which precludes compliance with the study (Investigator discretion).
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    NOTES Toolbox

    Multiple devices designed for trans-orifice use during surgical procedures; used for transvaginal cholecystectomy in this trial

    Device: Transgastric diagnostic peritoneoscopy with laparoscopic assistance

Interventions

  • DeviceTransgastric diagnostic peritoneoscopy with laparoscopic assistance

    Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)

06

What researchers measure

Primary outcomes

  1. Completion of Diagnostic Peritineoscopy

    Number of participants in which transgastric access was achieved using the EES NOTES GEN1 Toolbox Outcome description: Completion of diagnostic peritoneoscopy after transgastric access was completed using a flexible, steerable trocar. Because this was a feasibility trial, transgastric access was the primary outcome.

    Time frame: Assessed intra-operatively as the time from first insertion of the flexible trocar into the oral cavity to final withdrawal of the flexible trocar

07

Results

Posted Mar 29, 2012
Limitations and caveats
Ten male and female subjects indicated for Diagnostic Peritoneoscopy in advance of Roux-en Y Gastic Bypass procedure, who had a history of previous abdominal surgery, and met study Inclusion Criteria, were enrolled in the study.

Participant flow

Study Initiation Date: 09 June 2009 (First Informed consent signed) Study Completion Date:03 May 2010 (Last subject last visit) Enrollment Location: The Ohio State University Medical Center

Participant flow — Overall Study
MilestoneNatural Orifice Transgastric Diagnostic Peritineoscopy
Started10
Completed8
Not completed2
Withdrew: Transgastric dp was not completed2

Outcome measures

PrimaryCompletion of Diagnostic Peritineoscopy

Number of participants in which transgastric access was achieved using the EES NOTES GEN1 Toolbox Outcome description: Completion of diagnostic peritoneoscopy after transgastric access was completed using a flexible, steerable trocar. Because this was a feasibility trial, transgastric access was the primary outcome.

Time frame:
Assessed intra-operatively as the time from first insertion of the flexible trocar into the oral cavity to final withdrawal of the flexible trocar
Reported as:
Number · Participants
Completion of Diagnostic Peritineoscopy
ParticipantsNatural Orifice Transgastric Diagnostic Peritineoscopy
Completion of Diagnostic Peritineoscopy8

Adverse events

Collected over Adverse events were collected from Study Initiation Date (first Informed Consent signed) 09 June 2009 until Study Completion Date (last participant's last visit) on 03 May 2010.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Natural Orifice Transgastric Diagnostic Peritineoscopy—1/10 (10%)0/10 (0%)
Most frequent serious events
Most frequent serious events
EventNatural Orifice Transgastric Diagnostic Peritineoscopy
ESOPHAGEAL INJURY/ OESOPHAGEAL INJURYSurgical and medical procedures1/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Natural Orifice Transgastric Diagnostic Peritineoscopy
<=18 years0
Between 18 and 65 years9
>=65 years1
Age Continuous
Age Continuous(years)Natural Orifice Transgastric Diagnostic Peritineoscopy
Mean54.2 ± 9.76
Sex: Female, Male
Sex: Female, Male(Participants)Natural Orifice Transgastric Diagnostic Peritineoscopy
Female9
Male1
Region of Enrollment
Region of Enrollment(participants)Natural Orifice Transgastric Diagnostic Peritineoscopy
United States10
08

Study locations

1 site
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 29, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00962650
Lead sponsor
Ethicon Endo-Surgery
Responsible party
Sponsor
First posted
Aug 20, 2009
Start date
Jun 2009
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Mar 29, 2012
Last update
Mar 29, 2012

Study contacts

Jeffrey W Hazey, MD, FACS
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion